Home / Anti-infectives / Imipenem, Cilastatin and Relebactam
ATC J01DH56 · Carbapenems · updated 2 Nov 2026
Imipenem, Cilastatin and Relebactam shortage
As of 2 Nov 2026, Imipenem, Cilastatin and Relebactam has a reported shortage in 1 of the 16 countries we track (United States), covering 1 product from 1 company.
Is there an Imipenem, Cilastatin and Relebactam shortage?
Yes. As of 2 Nov 2026, Imipenem, Cilastatin and Relebactam is reported short in 1 of the 16 countries we track: United States. No company has given a return date.
Timeline
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Which companies are short
products short, all countriesListed: Merck & Co. (MSD) MRK · NYSE
Compared with similar medicines
ATC group J01DH · CarbapenemsAffected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | RECARBRIO, Injection, 500 mg/100 mL; 500 mg/100 mL; 250 mg/100 mL (NDC 0006-3856-02) discontinuation | Merck Sharp & Dohme LLC | 9 Sep 2026 | not given | Not stated |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.
Questions
Is there an Imipenem, Cilastatin and Relebactam shortage?
Yes. As of 2 Nov 2026, Imipenem, Cilastatin and Relebactam is reported short in 1 of the 16 countries we track: United States. No company has given a return date.
When will Imipenem, Cilastatin and Relebactam be back in stock?
No return date has been given; United States: no date given. These are company estimates reported to each authority.
Why is Imipenem, Cilastatin and Relebactam in short supply?
The most common reason reported is: not stated. Reasons by product are listed in the table below.
Which companies have Imipenem, Cilastatin and Relebactam shortages?
Merck & Co. (MSD).